AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03819920 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Risk Assessment (CCRAT)
Description: Patient receive personalized colorectal cancer risk assessment over the telephone by answering the questions as outlined in the National Cancer Institute Colorectal Cancer Risk Assessment Tool (https://ccrisktool.cancer.gov/calculator.html)
Study NCT03819920 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care (UC)
Description: Patients receive standardized general information about colorectal cancer screening over the telephone.
Study NCT03819920 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care (UC)
Description: Patients receive standardized general information about colorectal cancer screening over the telephone.
Study NCT01737541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Study NCT01737541 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03723837 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Polio Vaccine (IPV)
Description: Children receive one or two doses of IPV based on study arm they fall in
Study NCT03738787 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreatic duct occlusion with Neoprene
Description: Pancreatic duct occlusion of the pancreatic stump with Neoprene-based glue after Pancreatoduodenectomy.
Study NCT03738787 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreato-Jejunal anastomosis
Description: Standardized pancreato-jejunal anastomosis after Pancreatoduodenectomy
Study NCT03677908 — intervention group
Intervention type: OTHER
Intervention: ElectroEncephaloGraphy
Description: Density ElectroEncephaloGraphy analysis
Study NCT00331162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alemtuzumab
Description: 30 mg/100ml NS intraoperatively. Start after dexamethasone administration and prior to reperfusion of the allograft. Infuse over a minimum of 2 hours.
Study NCT00331162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Thymocyte Globulin
Description: 1.5 mg/kg per dose through a central line intraoperatively and on POD# 2 and 4, then continue on alternate days until a therapeutic tacrolimus(or cyclosporine) level is achieved, or until the SCr \< 3-4 mg/dL.~Give first dose over 6 hours, subsequent doses over 4 hours.~Premedication to be given with the first 3 doses:~Tylenol 650mg PO/PR Benadryl 25-50mg PO/IV Daily scheduled corticosteroid dose or other corticosteroid as deemed appropriate.~Hold infusion if temperature > 100.5ºF; Adjust dose for low WBC or Plt count Peripheral Thymoglobulin administration: Prepare dose in 500cc NS; Add heparin 1,000 units and hydrocortisone 20mg to the bag; Infuse over a minimum of 6 hours
Study NCT01728740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose/Metformin FDC (BAY81-9783)
Description: Acarbose/Metformin FDC (BAY81-9783)50mg/500mg, oral, single dose
Study NCT01728740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose (Glucobay, BAYG5421)
Description: Acarbose (Glucobay, BAYG5421) 50mg, oral, single dose
Study NCT03109015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: Patients randomized to sunitinib schedule 4/2 will receive sunitinib at 50 mg daily for 4 weeks on, followed by 2 weeks off, per standard of care. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline, 4 weeks and 12 weeks.
Study NCT03109015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Patients randomized to sunitinib schedule 2/1 will receive sunitinib 50 mg daily for 2 weeks on, followed by 1 week off. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline, 5 weeks and 12 weeks.
Study NCT03116282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-alcohol therapy
Description: Conversational therapy sessions provided via video conference by a professional alcohol therapist.
Study NCT04221035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.5 mg/m2 (max dose 2 mg)
Study NCT04221035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 750 mg/m2
Study NCT04221035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 175 mg/m2
Study NCT04221035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vindesine
Description: 3 mg/m2/day (max dose 6 mg)
Study NCT04221035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: 200 mg/m2/day
Study NCT04221035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 1500 mg/m2/day
Study NCT04221035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 30 mg/m2/dose
Study NCT04221035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: \< 9kg: 1.0 mg/kg/dose 9 kg to \< 16 kg : 1.2 mg/kg/dose 16 kg to 23 kg : 1.1 mg/kg/dose >23 kg to 34 kg: 0.95 mg/kg/dose >34 kg: 0.8 mg/kg/dose Infusion IV over 2 hours Administration every 6 hours for a total of 16 doses
Study NCT04221035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m2/dose IV short infusion (15'), at least 24 h after the last busulfan dose
Study NCT04221035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 300 mg/m2/day over 2 hours
Study NCT04221035 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 21.6 Gy 21.6 Gy + boost de 14.4 Gy
Study NCT04221035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinutuximab Beta
Description: Patients >12 kg are dosed based on the BSA: 10 mg/m\^2/day Patients ≤ 12 kg are dosed according to their body weight: 0.33 mg/kg/day
Study NCT04221035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80 mg/m2/24h
Study NCT04221035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide 100 MG
Description: 100 mg/m²/Day
Study NCT04221035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 50 mg/m²/jour de J0 à J4
Study NCT04221035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamid
Description: Cyclophosphamide has been demonstrated to have a cytostatic effect in many tumour types. The active metabolites of cyclophosphamide are alkylating agents which transfer alkyl groups to DNA during the process of cell division, thus preventing normal synthesis of DNA.
Study NCT03591289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NMB with rocuronium bromide
Description: Moderate versus deep neuromuscular block Not a device study
Study NCT04327037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Expanded Haploidentical Natural Killer cells
Description: One dose (from 20x to >100x 10\^6 /kg) of expanded haploidentical NK cells
Study NCT04327037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: 6 doses of IL-2 (1 × 10\^6 units/m2) from -1 day every other day.
Study NCT02283645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 % minoxidil lotion
Study NCT02283645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04572295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7090
Description: E7090 oral tablet.
Study NCT04572295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant intramuscular injection.
Study NCT04572295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane oral tablet.
Study NCT01303861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: For the first 3 days after being switched from nicotine patches (occurring at one week before the target quit date), smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
Study NCT01303861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: For the first 3 days after being switched from nicotine patches (occurring at one week before the target quit date), smokers in this group will receive bupropion at a dose of 150mg once per day. Subsequently, the dose will be 150mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
Study NCT02819193 — intervention group
Intervention type: OTHER
Intervention: raw mother's own milk
Description: Infants receive mother's own milk before day 7.
Study NCT01303861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patches
Description: Nicotine Replacement Therapy Groups:~1. For smokers with high baseline carbon monoxide (CO): 42 mg/24 h for 2 weeks before the quit date and 3 weeks after the quit date, 21 mg/24 h for 4 weeks, 14 mg/24 h for 2 weeks, and 7 mg/24 h for 2 weeks; or~2. For smokers with low baseline CO: 21 mg/24 h for 2 weeks before the quit date and 7 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks.~Varenicline and varenicline in combination with bupropion groups:~1. For smokers with high baseline CO: 42 mg/24 h for 1 week~2. For smokers with low baseline CO: 21 mg/24 h for 1 week
Study NCT01303861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Inhaler
Description: Nicotine inhaler to use as needed after quit date
Study NCT00659360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saracatinib
Description: Given orally
Study NCT00124982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: IV solution, IV infusion, between 500mg and 1gram based on body weight, monthly, 6 months.
Study NCT00124982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
Description: During the study, subjects continued to receive 1 or more background non-biologic DMARDs (e.g. methotrexate, leflunomide) at the dose level(s) and regimen(s) administered at the time of abatacept treatment onset (Day 1).
Study NCT00124982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Tumor Necrosing Factor (TNF) Therapy
Description: Any of the anti-TNF therapies (Infliximab, Adalimumab, Etanercept, etc.)administered at the approved label dose for at least 3 months
Study NCT03687385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-flow nasal oxygenation (HFNO)
Description: Experimental HFNO: O2 flow 40L/min, FiO2 40%
Study NCT03687385 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low-flow nasal oxygenation (LFNO)
Description: Active comparator LFNO: O2 flow 5L/min, FiO2 40%
Study NCT01359007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan, Oxaliplatin, Leucovorin, 5-FU
Description: 5-FU 2400 mg/m2 IV continuous infusion for 46-48 hours Days 1-3 for 2 weeks 5-FU 400 mg/m2 IV Bolus Day 1 Oxaliplatin 85 mg/m2 IV over 120min +/-30 min. Day 1 Irinotecan 180 mg/m2 IV to run over 90 min +/- 30 min Day 1 Leucovorin (Before bolus 5-FU) 400 mg/m2 IV over 120 min. +/- 30 Day 1 May give oxaliplatin and leucovorin concurrently
Study NCT03965767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: comparison of effect of tranexamic acid on control of bleeding when used locally in the nose or systemic use
Study NCT03965767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic Acid
Description: comparison of effect of tranexamic acid on control of bleeding when used locally in the nose or systemic use
Study NCT02144129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: active Whole Body Electromyostimulation
Study NCT01107977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Iyengar yoga
Description: Iyengar yoga twice/week for 6 weeks
Study NCT02144129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive WB-EMS
Study NCT02144129 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WB-EMS application
Study NCT01853917 — intervention group
Intervention type: OTHER
Intervention: questionaires and structured interviews
Description: We will do questionaires on pregnant women before they have their baby and after they have their baby. We will do structured interviews after they have their baby
Study NCT03378765 — intervention group
Intervention type: BEHAVIORAL
Intervention: Diet and physical activity monitoring
Description: Lifestyle monitoring
Study NCT03323840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incentivized Care
Description: Patients will receive a $10 gift card for every blood pressure measurement (up to 2 times/month)
Study NCT03153111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macitentan
Description: macitentan 10 mg; film-coated tablet; oral use
Study NCT02040844 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762]
Study NCT02040844 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762]
Study NCT02040844 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762]
Study NCT02214251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PK-16CH EXG system
Study NCT00946192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal 17Beta-estradiol, progesterone
Description: 100 mcg/day 17Beta-estradiol; transdermal twice weekly application for 12 months (with cyclic micronized progesterone pills (Prometrium): 200 mg taken orally daily Day 1 to Day 12 each month) + Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
Study NCT00946192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethinyl Estradiol + Desogestrel
Description: Oral ethinyl estradiol (0.03 mg) + desogestrel (0.15 mg) + Elemental calcium 1200 mg and Vit D 400 IU taken once daily
Study NCT00946192 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
Study NCT00070954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ginkgo biloba
Description: EgB 761
Study NCT00070954 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: matched placebo
Description: Inactive look-alike placebo
Study NCT04244591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone therapy
Description: Methylprednisolone 40 mg q12h for 5 days
Study NCT04244591 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Standard care
Study NCT00186810 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan, Cyclophosphamide, Horse ATG
Description: Transplant recipients received a myeloablative conditioning regimen of cyclophosphamide, Anti-Thymocyte Globulin (horse), and Busulfan. Cyclosporine and methotrexate were administered for GVHD prophylaxis.
Study NCT00186810 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Allogeneic stem cell transplant
Description: Allogeneic stem cell transplant Matched sibling donor transplant Cord blood transplant
Study NCT01719536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Icotinib: 125 mg is administered orally three times per day.
Study NCT01719536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: First-line chemotherapy: pemetrexed/cisplatin for 4 cycles. Maintenance treatment: pemetrexed.
Study NCT04248829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib 240 mg/160 mg
Description: The initial dose of lazertinib 240 mg (3 tablets of 80 mg lazertinib) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib) under specific circumstances
Study NCT03153111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: film-coated tablet (identical to the macitentan tablet); oral use
Study NCT01975935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlexanox
Description: 25 mg amlexanox tablets blinded by encapsulation
Study NCT01975935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo sham blinded by encapsulation in the same capsules as the study drug arm
Study NCT04248829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib 250 mg
Description: The initial dose for Gefitinib (250 mg once daily) cannot be reduced to a lower dose
Study NCT04248829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lazertinib-matching placebo 240 mg/160 mg
Description: The initial dose of lazertinib-matching placebo 240 mg (3 tablets of 80 mg lazertinib-matching placebo) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib-matching placebo) under specific circumstances
Study NCT04248829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib-matching placebo 250 mg
Description: The initial dose for Gefitinib-matching placebo (250 mg once daily) cannot be reduced to a lower dose
Study NCT02549443 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Amino acids
Description: AA (Travasol Baxter, Deerfield IL) during and after surgery in an amount equivalent to 20% and 35% of the patient's energy expenditure (EE)
Study NCT01634919 — intervention group
Intervention type: DEVICE
Intervention: chronic hepatitis C
Description: acoustic radiation force impulse ultrasonography
Study NCT00968331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide plus Rituximab
Description: Oral Lenalidomide is initiated on day 1 of cycle 1 at the dose of 20 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles. Rituximab is administered on day 1 and day 21 of each cycle at the dose of 375 mg/m2 for a total of 4 cycles.
Study NCT03105102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Risankizumab SC
Description: Placebo for Risankizumab SC Subcutaneous (SC) Injection
Study NCT01728740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 500mg, oral, single dose
Study NCT06081140 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard Process Hemp Oil Complex
Description: 10 days of supplementation to determine the tolerance and palatability of Standard Process Hemp Oil Complex.
Study NCT06614023 — intervention group
Intervention type: PROCEDURE
Intervention: coronary artery bypass grafting
Description: surgical coronary revascularization
Study NCT06614374 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-dose fish oil capsules
Description: Patients in the low-dose group will receive four fish-oil and refined olive oil mixed capsules containing 1.5 g of marine n-3 PUFAs per day.
Study NCT06614374 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-dose fish oil capsules
Description: Patients in the high-dose group will receive four fish oil capsules containing 3 g of marine n-3 PUFAs (72% EPA and 28% DHA) per day.
Study NCT06614374 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Refined olive oil
Description: Participants in the control group will receive 4 g refined olive oil daily
Study NCT03397914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistimethate Sodium
Description: Intravenous injection of colistimethate Sodium 2.5 mg/kg or 5 mg/kg for Multidrug-resistance gram negative infections
Study NCT04223284 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: D-Limonene
Description: Patient will put the aspUraclip®, a commercially available mini-inhalator filled for our study purpose filled with 1% D-Limonene in the nose for 15 minutes
Study NCT03484182 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based Home Exercise Program
Description: Home exercises that are guided by a web-based program
Study NCT03484182 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Home Exercise Program
Description: Standard paper-based home exercise program
Study NCT03105102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Risankizumab SC
Description: Placebo for Risankizumab SC Subcutaneous (SC) Injection
Study NCT03105102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab IV
Description: Risankizumab IV Intravenous (IV) infusion
Study NCT04223284 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SLVO
Description: Patient will put the aspUraclip®, a commercially available mini-inhalator filled for our study purpose filled with 1% SLVO in the nose for 15 minutes
Study NCT03105102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Risankizumab IV
Description: Placebo for Risankizumab IV Intravenous (IV) infusion
Study NCT03105102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab SC
Description: Risankizumab SC Subcutaneous (SC) injection
Study NCT03105102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab On-Body Injector (OBI)
Description: Subcutaneous (SC) injection; on-body injector (OBI)